Last reviewed · How we verify

Comparator: glimepiride — Competitive Intelligence Brief

Comparator: glimepiride (Comparator: glimepiride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea. Area: Diabetes.

marketed Sulfonylurea Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: glimepiride (Comparator: glimepiride) — Merck Sharp & Dohme LLC. Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Comparator: glimepiride TARGET Comparator: glimepiride Merck Sharp & Dohme LLC marketed Sulfonylurea Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel
Amaryl GLIMEPIRIDE Sanofi marketed Sulfonylurea [EPC] Sulfonylurea receptor 1, Kir6.2 1995-01-01
Micronase glibenclamide Sanofi marketed Sulfonylurea Sulfonylurea receptor 1, Kir6.2 1984-01-01
Glucotrol GLIPIZIDE Pfizer marketed Sulfonylurea [EPC] Sulfonylurea receptor 1, Kir6.2 1984-01-01
Aglicid TOLBUTAMIDE marketed Sulfonylurea Sulfonylurea receptor 1, Kir6.2 1961-01-01
Diabinese CHLORPROPAMIDE Pfizer marketed Sulfonylurea Sulfonylurea receptor 1, Kir6.2 1958-01-01
metformin, glyburide and glargine metformin, glyburide and glargine The University of Texas Health Science Center at San Antonio marketed Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin) Multiple: AMP-activated protein kinase (metformin), ATP-sensitive potassium channels (glyburide), insulin receptor (glargine)

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea class)

  1. Merck Sharp & Dohme LLC · 6 drugs in this class
  2. Pfizer · 2 drugs in this class
  3. Sanofi · 2 drugs in this class
  4. Janssen Research & Development, LLC · 1 drug in this class
  5. Samsung Medical Center · 1 drug in this class
  6. Servier Affaires Médicales · 1 drug in this class
  7. The George Institute · 1 drug in this class
  8. · 1 drug in this class
  9. University of Glasgow · 1 drug in this class
  10. GRADE Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: glimepiride — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-glimepiride. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: